Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran, +188

The Lancet Oncology

Egfrviii-expressing GlioblastomaNeuro-oncologyAct IvGliomaInternational Phase 3 +8

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

Miklos Pless, Roger Stupp, Hans-Beat Ris, +18

The Lancet

MedicineBronchial NeoplasmInduction ChemoradiationCancer TreatmentOncology +5

Epidermal Growth Factor Receptor–Targeted Immunoliposomes Significantly Enhance the Efficacy of Multiple Anticancer Drugs<i>In vivo</i>

Christoph Mamot, Daryl C. Drummond, Charles O. Noble, +5

Cancer Research

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy

Chulin Sha, Sharon Barrans, Francesco Cucco, +20

Journal of Clinical Oncology

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells

Christoph Mamot, Daryl C. Drummond, Udo Greiser, +4

The Women s Oncology Review

Cell-based Drug DeliveryIl AgentEfficient Drug DeliveryDrug TargetingImmunoliposomes Mediate Specific +13

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Andrew Davies, Thomas Cummin, Sharon Barrans, +21

The Lancet Oncology

Distribution of Liposomes into Brain and Rat Brain Tumor Models by Convection-Enhanced Delivery Monitored with Magnetic Resonance Imaging

Ryuta Saito, John R. Bringas, Tracy R. McKnight, +7

Cancer Research

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study

Christoph Mamot, Reto Ritschard, Andreas Wicki, +7

The Lancet Oncology

MedicineImmunologyPharmacologyAdvanced Solid TumoursDoxorubicin-loaded Anti-egfr Immunoliposomes +5

Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial

Rolf A. Stahel, Oliver Riesterer, Alexandros Xyrafas, +20

The Lancet Oncology

Surgical OncologyMalignant Pleural MesotheliomaRadiation TherapyMedicineSakk 17/04 +6

Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)

Christoph Mamot, Dirk Klingbiel, Felicitas Hitz, +15

Journal of Clinical Oncology